Effects of clonidine on alprazolam discontinuation in panic patients

A pilot study

Abby J. Fyer, Michael R. Liebowitz, Jack M. Gorman, Campeas Raphael, Levin Andrew, Sandberg Diana, Fyer Minna, Eric Hollander, Papp Laszlo, Deborah Goetz, Donald F. Klein

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Effects of adjunctive clonidine (0.15 to 0.7 mg/ day) on symptoms experienced during and for 4 weeks after gradual alprazolam discontinuation were observed in panic disorder patients after 6 weeks of successful treatment. Twelve of 14 entered patients were considered to have had a sufficient period of discontinuation (2 weeks) and clonidine administration (1 week) for effects to be assessed adequately. Nine of these 12 patients reached zero dose of alprazolam in 3 to 4 weeks. However, 10 of 12 patients experienced new withdrawal symptoms and 11 of 12 experienced recurrent panic attacks during tapering. Although a greater proportion of patients were successfully discontinued in a shorter time than in a previous nonclonidine trial, clonidine did not appear to have a specific effect on relapse or withdrawal. A placebo-controlled trial is needed to discriminate between possible contributions of clonidine and other factors (e.g., physician attitude, placebo effect of pi11 taking) to this improved outcome.

Original languageEnglish (US)
Pages (from-to)270-274
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume8
Issue number4
StatePublished - 1988
Externally publishedYes

Fingerprint

Alprazolam
Panic
Clonidine
Panic Disorder
Substance Withdrawal Syndrome
Placebo Effect
Placebos
Physicians
Recurrence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fyer, A. J., Liebowitz, M. R., Gorman, J. M., Raphael, C., Andrew, L., Diana, S., ... Klein, D. F. (1988). Effects of clonidine on alprazolam discontinuation in panic patients: A pilot study. Journal of Clinical Psychopharmacology, 8(4), 270-274.

Effects of clonidine on alprazolam discontinuation in panic patients : A pilot study. / Fyer, Abby J.; Liebowitz, Michael R.; Gorman, Jack M.; Raphael, Campeas; Andrew, Levin; Diana, Sandberg; Minna, Fyer; Hollander, Eric; Laszlo, Papp; Goetz, Deborah; Klein, Donald F.

In: Journal of Clinical Psychopharmacology, Vol. 8, No. 4, 1988, p. 270-274.

Research output: Contribution to journalArticle

Fyer, AJ, Liebowitz, MR, Gorman, JM, Raphael, C, Andrew, L, Diana, S, Minna, F, Hollander, E, Laszlo, P, Goetz, D & Klein, DF 1988, 'Effects of clonidine on alprazolam discontinuation in panic patients: A pilot study', Journal of Clinical Psychopharmacology, vol. 8, no. 4, pp. 270-274.
Fyer AJ, Liebowitz MR, Gorman JM, Raphael C, Andrew L, Diana S et al. Effects of clonidine on alprazolam discontinuation in panic patients: A pilot study. Journal of Clinical Psychopharmacology. 1988;8(4):270-274.
Fyer, Abby J. ; Liebowitz, Michael R. ; Gorman, Jack M. ; Raphael, Campeas ; Andrew, Levin ; Diana, Sandberg ; Minna, Fyer ; Hollander, Eric ; Laszlo, Papp ; Goetz, Deborah ; Klein, Donald F. / Effects of clonidine on alprazolam discontinuation in panic patients : A pilot study. In: Journal of Clinical Psychopharmacology. 1988 ; Vol. 8, No. 4. pp. 270-274.
@article{90f0d4b24d0a4068a4dc6e6b63c5012b,
title = "Effects of clonidine on alprazolam discontinuation in panic patients: A pilot study",
abstract = "Effects of adjunctive clonidine (0.15 to 0.7 mg/ day) on symptoms experienced during and for 4 weeks after gradual alprazolam discontinuation were observed in panic disorder patients after 6 weeks of successful treatment. Twelve of 14 entered patients were considered to have had a sufficient period of discontinuation (2 weeks) and clonidine administration (1 week) for effects to be assessed adequately. Nine of these 12 patients reached zero dose of alprazolam in 3 to 4 weeks. However, 10 of 12 patients experienced new withdrawal symptoms and 11 of 12 experienced recurrent panic attacks during tapering. Although a greater proportion of patients were successfully discontinued in a shorter time than in a previous nonclonidine trial, clonidine did not appear to have a specific effect on relapse or withdrawal. A placebo-controlled trial is needed to discriminate between possible contributions of clonidine and other factors (e.g., physician attitude, placebo effect of pi11 taking) to this improved outcome.",
author = "Fyer, {Abby J.} and Liebowitz, {Michael R.} and Gorman, {Jack M.} and Campeas Raphael and Levin Andrew and Sandberg Diana and Fyer Minna and Eric Hollander and Papp Laszlo and Deborah Goetz and Klein, {Donald F.}",
year = "1988",
language = "English (US)",
volume = "8",
pages = "270--274",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effects of clonidine on alprazolam discontinuation in panic patients

T2 - A pilot study

AU - Fyer, Abby J.

AU - Liebowitz, Michael R.

AU - Gorman, Jack M.

AU - Raphael, Campeas

AU - Andrew, Levin

AU - Diana, Sandberg

AU - Minna, Fyer

AU - Hollander, Eric

AU - Laszlo, Papp

AU - Goetz, Deborah

AU - Klein, Donald F.

PY - 1988

Y1 - 1988

N2 - Effects of adjunctive clonidine (0.15 to 0.7 mg/ day) on symptoms experienced during and for 4 weeks after gradual alprazolam discontinuation were observed in panic disorder patients after 6 weeks of successful treatment. Twelve of 14 entered patients were considered to have had a sufficient period of discontinuation (2 weeks) and clonidine administration (1 week) for effects to be assessed adequately. Nine of these 12 patients reached zero dose of alprazolam in 3 to 4 weeks. However, 10 of 12 patients experienced new withdrawal symptoms and 11 of 12 experienced recurrent panic attacks during tapering. Although a greater proportion of patients were successfully discontinued in a shorter time than in a previous nonclonidine trial, clonidine did not appear to have a specific effect on relapse or withdrawal. A placebo-controlled trial is needed to discriminate between possible contributions of clonidine and other factors (e.g., physician attitude, placebo effect of pi11 taking) to this improved outcome.

AB - Effects of adjunctive clonidine (0.15 to 0.7 mg/ day) on symptoms experienced during and for 4 weeks after gradual alprazolam discontinuation were observed in panic disorder patients after 6 weeks of successful treatment. Twelve of 14 entered patients were considered to have had a sufficient period of discontinuation (2 weeks) and clonidine administration (1 week) for effects to be assessed adequately. Nine of these 12 patients reached zero dose of alprazolam in 3 to 4 weeks. However, 10 of 12 patients experienced new withdrawal symptoms and 11 of 12 experienced recurrent panic attacks during tapering. Although a greater proportion of patients were successfully discontinued in a shorter time than in a previous nonclonidine trial, clonidine did not appear to have a specific effect on relapse or withdrawal. A placebo-controlled trial is needed to discriminate between possible contributions of clonidine and other factors (e.g., physician attitude, placebo effect of pi11 taking) to this improved outcome.

UR - http://www.scopus.com/inward/record.url?scp=0023786914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023786914&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 270

EP - 274

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -